Jason V. Coloma, Chief Executive Officer at Maze Therapeutics, Inc. (MAZE), sold 34,501 shares at $29.98 ($1.0M) on 2026-07-01, disclosed to the SEC on 2026-07-02.
Scheduled sale ($1.0M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $29.95 | 30,311 | $908K | 87.8% |
| 2 | $29.98 | 2,593 | $78K | 7.5% |
| 3 | $30.44 | 1,597 | $49K | 4.7% |
| Total | $29.98 avg | 34,501 | $1.0M | 100% |
| Filing → |
| MAZE | SELL | 2026-08-05 | $922K | — | Filing → |
| MAZE | SELL | 2026-06-24 | $725K | — | Filing → |
| MAZE | SELL | 2026-06-03 | $174K | — | Filing → |